FGP
NKTR icon

Freestone Grove Partners’s Nektar Therapeutics NKTR Stock Holding History

Freestone Grove Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
+2,217
New +$162K ﹤0.01% 818

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's NKTR Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 2,217 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #818 among its holdings.

240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Freestone Grove Partners held 2,217 shares of Nektar Therapeutics worth $155K as of Q2 2026.
  • Nektar Therapeutics was a new Freestone Grove Partners position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #818 holding.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.